{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:08:24Z","timestamp":1784005704356,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,14]]},"DOI":"10.7759\/cureus.41889","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T17:26:25Z","timestamp":1689355585000},"source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-Induced Hypothyroidism: A Case Report"],"prefix":"10.7759","author":[{"given":"Carlos","family":"Gaibor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayakumari","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll DM","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012, 12:252-64.","journal-title":"Nat Rev Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab HO","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017, 8:561. 10.3389\/fphar.2017.00561","journal-title":"Front Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2015.51.1.2250387","article-title":"Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer","volume":"51","author":"McDermott J","year":"2015","unstructured":"McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc). 2015, 51:7-20. 10.1358\/dot.2015.51.1.2250387","journal-title":"Drugs Today (Barc)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas A","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, et al.. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016, 315:1600-9. 10.1001\/jama.2016.4059","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents","volume":"21","author":"Weber JS","year":"2016","unstructured":"Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016, 21:1230-40. 10.1634\/theoncologist.2016-0055","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26143","article-title":"Pembrolizumab-induced acute skin reaction: a case report and review of literature","volume":"14","author":"Thomas M","year":"2022","unstructured":"Thomas M, Wazir A, Poudel A. Pembrolizumab-induced acute skin reaction: a case report and review of literature. Cureus. 2022, 14:e26143. 10.7759\/cureus.26143","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh AM","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020, 19:479-88. 10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14740\/jmc4008","article-title":"Pembrolizumab-induced myasthenia gravis and myositis: literature review on neurological toxicities of programmed death protein 1 inhibitors","volume":"13","author":"Schwab A","year":"2022","unstructured":"Schwab A, Assaad M, Hamadi R, et al.. Pembrolizumab-induced myasthenia gravis and myositis: literature review on neurological toxicities of programmed death protein 1 inhibitors. J Med Cases. 2022, 13:530-5. 10.14740\/jmc4008","journal-title":"J Med Cases"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-18-0153","article-title":"A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma","volume":"2019","author":"Hakami OA","year":"2019","unstructured":"Hakami OA, Ioana J, Ahmad S, Tun TK, Sreenan S, McDermott JH. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma. Endocrinol Diabetes Metab Case Rep. 2019, 2019:10.1530\/EDM-18-0153","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819896182","article-title":"Immunotherapy-induced endocrinopathies: assessment, management and monitoring","volume":"10","author":"Nogueira E","year":"2019","unstructured":"Nogueira E, Newsom-Davis T, Morganstein DL. Immunotherapy-induced endocrinopathies: assessment, management and monitoring. Ther Adv Endocrinol Metab. 2019, 10:10.1177\/2042018819896182","journal-title":"Ther Adv Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/164151-pembrolizumab-induced-hypothyroidism-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:02Z","timestamp":1707509102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/164151-pembrolizumab-induced-hypothyroidism-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.41889","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}